Peptide therapeutics are reshaping modern medicine, with GLP-1 receptor agonists driving rapid advances in metabolic disease treatment. As peptide and GLP-1 programs scale, scientists face increasing pressure to generate data that is accurate, defensible, and decision-ready across development stages.
Peptide 360 is designed to guide scientists through this complexity, following the peptide workflow from sequence insight to confident development decisions.
This series is designed for scientists and technical leaders working in peptide and GLP-1 discovery and development, analytical development, characterization, Bioanalysis, DMPK, translational research, CMC, QA/QC, and regulatory-facing analytical roles
As GLP-1 analogs increase in structural complexity, efficient impurity profiling requires both speed and structural clarity. This session presents a staged LC/MS-based workflow that enables rapid impurity screening to identify candidates requiring deeper investigation, followed by targeted ECD-based sequence analysis for detailed structural insight. By separating fit-for-purpose screening from high-resolution characterization, the workflow reduces unnecessary analytical complexity and shortens the path from detection to interpretation.
Attendees will learn how electron capture dissociation (ECD) preserves labile modifications, enabling precise localization and confident sequence confirmation. The session highlights how tiered impurity strategies support timely, data-driven decisions during GLP-1 development.
Presenter: Rachel Franklin (Application Development Scientist, Agilent Technologies, Inc.)
Presenter: Ashish Pargaonkar, Ph.D. (Biopharma Applications Specialist, Agilent Technologies, Inc.)
